Objective. Gain-of-function mutations in TMEM173, encoding the stimulator of interferon (IFN) genes (STING) protein, underlie a novel type I interferonopathy that is minimally responsive to conventional immunosuppressive therapies and associated with high frequency of childhood morbidity and mortality. STING gain-of-function causes constitutive oversecretion of IFN. This study was undertaken to determine the effects of a TANK-binding kinase 1 (TBK-1)/IKKE inhibitor (BX795) on secretion and signaling of IFN in primary peripheral blood mononuclear cells (PBMCs) from patients with mutations in STING.
The stimulator of interferon (IFN) genes (STING) protein is a major regulator of the innate immune response to viral and bacterial infections. Upon infection, STING promotes the activation of TANK-binding kinase 1 (TBK-1), leading to IFN regulatory factor 3 (IRF-3) translocation into the nucleus and type I IFN transcription. Secretion of IFN induces the expression of IFNstimulated genes (ISGs) through activation of the ISG factor 3 (ISGF-3) complex, composed of STAT-1, STAT-2, and IRF-9. Gain-of-function mutations in TMEM173, encoding STING, have been associated with an autoinflammatory syndrome termed SAVI (STING-associated vasculopathy with onset in infancy) (1) (2) (3) . STING-associated disease presents a wide phenotypic spectrum that includes systemic inflammation with fever, a severe skin vasculopathy leading, in some cases, to extensive tissue loss, and interstitial lung disease resulting in pulmonary fibrosis and end-stage respiratory failure (1, 2, 4) . Missense mutations in TMEM173 reported so far have been shown to be associated with constitutive activation of STING, resulting in increased IFNa production (5), phosphorylation of STAT-1 in T and B lymphocytes, and increased transcription of ISGs in peripheral whole blood (1, 2) . Thus, STING-associated disease can be classified as a type I interferonopathy (3) . These observations pave the way for 2 potential therapeutic strategies, one aiming to inhibit the secretion of IFN itself, and the other targeting the IFN receptor signaling cascade.
BX795 has been described as a specific inhibitor of TBK-1, and also an inhibitor of IKKE. BX795 acts through competitive inhibition of ATP binding (6) . This bispecificity can be explained by the high homology between TBK-1 and IKKE (7) . TBK-1 responds to STING activation by driving type I IFN transcription through the phosphorylation of IRF-3 (3), whereas IKKE inhibits the formation of STAT-1 homodimers favoring the formation of the ISGF-3 complex and ISG transcription (7) . Therefore, for the present study, we postulated that IKK inhibitors may reduce the overproduction of IFN in STING-mutated patient cells through inhibition of TBK-1, and may also restrict the transcription of ISGs through IKKE inhibition (as shown in Figure 1A ).
PATIENTS AND METHODS
Patients. Four children carrying de novo or inherited gain-of-function mutations in TMEM173 were recruited. A positive type I IFN signature (8) was observed in all patients. The disease-specific phenotypic details for each of the 4 children are available upon request from the corresponding author. The study received ethics approval from the Comit e de Protection des Personnes (ID-RCB/EUDRACT no. 2014-A01017-40).
Cell cultures. Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll-Paque density gradient (LymphoPrep; Proteogenix) from the blood of patients and healthy donors. Fresh or cryopreserved PBMCs were used for the assays. PBMCs were cultured at 378C in 5% CO 2 in GlutaMax RPMI 1640 medium (Invitrogen), supplemented with 10% (volume/volume) fetal bovine serum, 100 units/ml penicillin, and 100 mg/ml streptomycin (each from Gibco). The PBMCs were thereafter treated with 2 mM BX795 or DMSO as a control.
Human embryonic kidney cells (HEK 293T cells) were grown in 96-well plates at 378C in 5% CO 2 in Dulbecco's modified Eagle's medium supplemented with 10% (v/v) fetal bovine serum, 100 units/ml penicillin, and 100 mg/ml streptomycin (each from Gibco). Once the HEK 293T cells had reached 70% confluence, they were cotransfected with 60 ng of a pMSCV-hygro(1) vector, either empty or encoding the TMEM173 pV.155M variant, 40 ng of IFNb promoter-driven firefly luciferase reporter plasmid (IFNb-pGL3), and 1.4 ng of constitutively expressed Renilla luciferase reporter plasmid (pRL-TK), using a TransIT-293 transfection reagent (Mirus no. MIR2700; Euromedex). Twenty-four hours later, the cells were stimulated by transfection with 1.3-12 mg/ml 2 0 3 0 -cyclic GMP-AMP (cGAMP)-STING ligand (tlrl-nacga23; InvivoGen) using Lipofectamine 2000 (Thermo Fisher Scientific). Subsequently, the cells were treated with 2 mM BX795 or with DMSO as a control.
Twenty-four hours after cGAMP stimulation, the cells were lysed with passive lysis buffer 5X (Promega) containing protease and phosphatase inhibitors. One-third of the lysate for each condition was used for the luciferase assay. The remaining material was used for protein analysis by Western blotting.
IFNb promoter-driven luciferase (IFN-Luc) reporter assay. An IFNb-pGL3 plasmid was used to measure IFNb promoter activity, and a Renilla reporter plasmid was used as a control to normalize the transfection efficiency. Luciferase assays were performed using a Dual-Glo Luciferase Assay System (E2940; Promega) in accordance with the manufacturer's protocol. Luminescence was acquired on a FLUOstar OPTIMA microplate reader (BMG Lab Technologies). The values for firefly luciferase activity were normalized against those for Renilla luciferase activity.
Western blot analysis. Proteins were extracted from PBMCs and from transfected HEK 293T cells using lysis buffer (radioimmunoprecipitation assay buffer containing 1% protease inhibitor and 1% phosphatase inhibitor). Bolt LDS Sample Buffer (4X) and Bolt Sample Reducing Agent (10X) (both from Novex Life Technologies) were added to the protein lysates, and the samples were resolved on 4-12% Bis-Tris Plus gels (Invitrogen) transferred to nitrocellulose membrane (Invitrogen). When the phosphorylation status of the protein was investigated, membranes were blocked in 5% bovine serum albumin (BSA) in Tris buffered saline (TBS), and primary phospho-antibodies were incubated overnight in blocking solution. Alternatively, membranes were blocked with 5% nonfat milk in TBS, and thereafter primary antibodies were incubated overnight in blocking solution.
Proteins were blotted with mouse anti-STING antibodies, rabbit anti-IRF-3 antibodies, mouse anti-IRF-9 antibodies, mouse anti-pIRF-3 antibodies, rabbit anti-pTBK-1 antibodies, and rabbit anticofilin antibodies (as loading control) (all from Cell Signaling Technology), diluted in 5% BSA-TBS (1X)-0.1% Tween for 1 hour at room temperature. Membranes were incubated with the appropriate anti-mouse or anti-rabbit secondary antibodies for 45 minutes at room temperature (R&D Systems). Signal was detected using an enhanced chemiluminescence and ChemiDoc MP quantification system (Bio-Rad) or using an 1496 FR EMOND ET AL Odyssey CLx system (Li-Cor). Comparative signal analyses were performed using Image Lab (Bio-Rad) and Image Studio Lite (Li-Cor).
Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) analysis of gene expression. PBMCs were left untreated or treated with 2 mM BX795 at 378C for 24 hours. Total RNA was extracted using an RNAqueous-Micro kit (Ambio). RT was performed using a High-Capacity cDNA Reverse Transcription kit (Applied Biosystems). Levels of messenger RNA (mRNA) were quantified by qRT-PCR using a TaqMan gene expression assay (Applied Biosystems), with values normalized to the expression levels of housekeeping gene HPRT1. A complete list of the probes used in this study is available upon request from the corresponding author.
Assay for STAT-1 phosphorylation. PBMCs were left untreated or treated with 2 mM BX795 at 378C for 4 hours (short-term stimulation) or overnight. Cells were fixed using BC PerFix Expose Fixation Buffer (10 minutes at room temperature), and then permeabilized using BC PerFix Expose Permeabilizing Buffer (5 minutes at 378C). Cells were then protected from light and stained with phycoerythrin (PE)-conjugated anti-STAT1 pY701, PE-conjugated anti-STAT1, and cell surface markers (allophycocyanin-conjugated CD3, BV421-conjugated CD8, and PE-Cy7-conjugated CD19) for 1 hour at room temperature. Flow cytometry analysis was performed on a Gallios Beckman Coulter flow cytometer. Results were analyzed using Kaluza software version 1.3.
Quantification of IFNa in serum and PBMCs by Simoa assay. The Simoa IFNa assay was developed using a Quanterix Homebrew Simoa assay kit in accordance with the manufacturer's instructions, utilizing 2 autoantibodies specific for IFNa isolated and cloned from 2 recently described patients with autoimmune polyendocrinopathy syndrome type 1/autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (5, 9) . The 8H1 antibody clone was used as a capture antibody, after coating on paramagnetic beads (0.3 mg/ml), and the 12H5 antibody was biotinylated (biotin-to-antibody ratio 30: 1) and used as the detector. Recombinant IFNa17/aI (PBL Assay Science) was used to generate a standard curve, after cross-reactivity testing. The limit of detection was calculated as the mean 1 3SD value of reactivity from all blank runs, found to be 0.23 fg/ml.
Statistical analysis. Analyses were performed with Prism software (version 6 for Macintosh; GraphPad). Data were tested for normality using the D'Agostino and Pearson test. Data are expressed as the mean 6 SD. P values less than 0.05 were considered significant.
RESULTS
Inhibition of type I IFN production by BX795 in HEK 293T cells and PBMCs from patients with STING mutations. Activation of STING by cGAMP is known to promote the activation of IRF-3 and the subsequent transcription of type I IFN. Using an IFN-Luc reporter assay, we showed that BX795 treatment decreased the cGAMP-dependent overexpression of IFNb in HEK 293T cells ( Figure 1B) .
In order to validate the hypothesis that BX795 treatment might prove beneficial in patients carrying gainof-function mutations in STING, we repeated this experiment using a p.V155M plasmid encoding the Val Figure 1D ). These data suggest that IRF-3 phosphorylation is required for mutant STING-induced type I IFN transcription (10) . Thus, our findings validate the hypothesis that IKKE inhibitors might be used to control IFN production in patients with SAVI.
To further test this possibility, we isolated PBMCs from the blood of 3 patients with gain-of-function mutations in STING. Using an ultrasensitive digital enzyme-linked immunosorbent assay to quantify IFNa (5), we observed significantly higher levels of both intracellular IFNa and secreted IFNa in patient-derived PBMCs as compared to healthy control PBMCs (for intracellular IFNa, mean 6 SD 10,108 6 13,768 fg/ml versus 15.87 6 15.17 fg/ml, and for secreted IFNa, mean 6 SD 11,330 6 14,461 fg/ml versus 0.67 6 0.01 fg/ml; each P , 0.05). Furthermore, BX795 treatment decreased the IFNa concentration in total PBMC lysates and supernatants derived from patients with mutations in STING as compared to DMSO-treated control cells (Figures 1E and F) . These results were independent of PBMC survival, since BX795 did not affect cell viability at this working concentration (details available upon request from the corresponding author).
Inhibition of STAT-1 phosphorylation and ISG expression by BX795 in cells from patients with STING mutations. As previously reported (1, 11) , increased levels of STAT-1 phosphorylation were observed in lymphocytes from patients with STING mutations as compared to lymphocytes from healthy controls (Figures 2A and C) (further details available upon request from the corresponding author). In order to evaluate the impact of BX795-induced IKKE inhibition on ISG transcription, as opposed to regulation of ISG transcription through reduction of IFN secretion via inhibition of TBK-1, we examined the STAT-1 phosphorylation status and ISG levels after short-term treatment of PBMCs from 4 patients carrying mutations in STING. After 4 hours of treatment with BX795, we observed a partial reduction of STAT-1 phosphorylation in T and B lymphocytes from 2 patients (Figure 2A ). After 6 hours of treatment, the expression of 5 ISGs was decreased in patient cells ( Figure 2B ), thus indicating an IFN-independent inhibition of ISG transcription by BX795 that likely occurs through inhibition of IKKE.
To assess the overall effect of IKK inhibition on IFN signaling, we evaluated the levels of pSTAT-1 and ISGs in PBMCs from 4 patients after overnight treatment with BX795. This extended time course is sufficient to allow transcription and secretion of IFN, and to observe the subsequent IFN-driven phosphorylation of STAT-1 and transcription of ISGs. In vitro, BX795 treatment resulted in the inhibition of STAT-1 phosphorylation in T and B lymphocytes from all patients with STING mutations (representative results in 1 patient shown in Figure 2C ). Consistently, treatment with BX795 was associated with a decrease in the expression of 5 ISGs in PBMCs from all 4 patients ( Figure 2D) .
Inhibition of TMEM173 and IRF-9 expression by BX795 in cells from patients with STING mutations. Consistent with our hypothesis that IFN secretion and ISG transcription could simultaneously be targeted in cells from patients with mutations in STING, we investigated the effect of BX795 treatment on the expression of TMEM173/STING itself and on the expression levels of IRF-9 mRNA and protein, since the former drives type I IFN production in patients and the latter is an essential component of the ISGF-3 transcription complex responsible for ISG expression. Following treatment with BX795, we observed a reduction in both TMEM173 and IRF9 transcripts in PBMCs from all patients ( Figure 3A ). This was confirmed at the protein level in both HEK 293T cells and PBMCs from 3 patients, with decreases in protein levels ranging 41-73% for IRF-9 and 20-32% for STING ( Figures 3B-D) (further details available upon request from the corresponding author). The reduction in the expression of IRF-9 and STING by BX795 indicates that the treatment simultaneously inhibits not only the signaling cascade responsible for type I IFN and ISG transcription, but also the expression of key molecules in these pathways, thus highlighting a virtuous circle in the context of BX795 treatment of cells from patients carrying mutations in STING.
DISCUSSION
This study is the first to demonstrate the effect of TBK-1/IKKE inhibition in the context of gain-of-function mutations in STING. We assessed the effect of BX795 on the different steps of IFN signaling-from the constitutive overexpression of type I IFN to the increased expression of ISGs via the JAK/STAT pathway. Features of inflammation attributable to STING gain-of-function are associated with a high incidence of childhood morbidity and mortality. To date, conventional immunosuppressive therapies have proven to be minimally effective in this disease. We have previously demonstrated the benefit of JAK-1/2 inhibition in 3 children carrying activating mutations in STING (11) . However, this treatment, at the current posology, inhibits the JAK-1/2 pathway only transiently, and does not allow for complete remission of disease features (11) . Moreover, we observed a sustained growth defect in treated patients, possibly explained by the role of JAK-2 in growth hormone signaling (12) , and hematologic side effects occurred frequently in patients with myelofibrosis who received treatment with JAK-1/2 inhibition (13).
Thus, alternative therapeutic strategies are urgently required.
Herein we demonstrate that targeting IKKE is another strategy to inhibit ISG transcription in patient cells. However, inhibition of IKKE or JAK prevents type I IFN signaling but does not abrogate the overproduction of IFN itself (12, 14) . Targeting STING or its immediate partners, such as TBK-1 or IRF-3, may be relevant to avoid constitutive type I IFN expression in STINGassociated vasculopathy, and may therefore represent a valuable therapeutic option.
Interestingly, the lethality of autoinflammation in Trex1 2/2 mice is significantly rescued when this mouse strain is backcrossed on Irf3 1/2 mice (15), suggesting that even partial IRF-3 inhibition, with a preserved antiviral response, might be sufficient to provide clinical benefit. In the present study, we demonstrated that TBK-1/IKKE inhibition decreased the production of IFNa by patient PBMCs, and thus this treatment appears to effectively target the first stage of the inflammatory response. This is of particular interest knowing that TMEM173 and IRF9 are themselves ISGs (16) , most likely acting to further amplify the constitutive activation of type I IFN signaling in patients with STING mutations. Consistently, the levels of IRF9 and TMEM173 mRNA and protein were reduced under BX795 treatment, thus highlighting a virtuous circle in the control of disease-associated inflammation in patient cells. Given that STING drives the IFN response in patients with systemic lupus erythematosus (SLE) (17) , and that TBK-1 inhibition was recently shown to promote the reduction of the IFN signature in SLE patient-derived leukocytes, we predict that the benefit of combined TBK-1/IKKE inhibition may apply not only to the monogenic interferonopathies, but also to certain complex autoimmune diseases (18) .
In conclusion, this report describes, for the first time, the effect of TBK-1/IKKE inhibition treatment on cells from patients with gain-of-function mutations in STING. BX795 treatment reduced both IFNa production and ISG transcription in patient cells. These findings thus support the development of pharmacologic inhibitors of IKK suitable for clinical use in the treatment of STINGassociated autoinflammation. Such compounds might also be relevant as a therapeutic option in other monogenic type I interferonopathies and complex autoimmune diseases such as SLE.
